Neogen Corporation Common Stock (NEOG)

FairStock Score: 43/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Graham-and-Buffett-style investor, I begin with business quality. Neogen sells diagnostic tests and related products for food and animal safety, a market with regulatory and safety-driven demand. That can create a modest moat, but the financials must confirm it, and they do not yet. In fiscal 2026, the year ended 2026-05-31, revenue was $870.4 million and net income was -$7.9 million, or diluted EPS -$0.04. Fiscal 2025, the year ended 2025-05-31, produced a $1.1 billion loss and diluted EPS -$5.03. Fiscal 2024, the year ended 2024-05-31, had revenue of $924.2 million and a $9.4 million loss. Sales have therefore slipped from $924.2 million to $870.4 million over two years. More recently, in fiscal Q1 2027, the quarter ended 2026-08-31, revenue was $222.8 million and net income was -$11.9 million, or EPS -$0.05. That is above fiscal Q1 2026, the quarter ended 2025-08-31, revenue of $209.2 million, but the company remains unprofitable. Debt-to-equity is 0.39, so leverage is not extreme, yet FairStock's Altman Z-Score of 1.23 suggests distress risk and its Piotroski F-Score is 5/9. Trailing free cash flow is $31.9 million, only a 1.2% FCF yield on a $2.6 billion market cap. At the $11.73 close on 2026-10-13, FairStock shows P/B of 1.22 and EV/EBITDA of 18.42; the negative P/E of -293.25 is not meaningful. This looks like a turnaround, not a clear bargain.

In plain English: Neogen makes tests and products used to keep food and animal feed safe. The business is not currently profitable, with losses in recent years and sales that have drifted lower, though it still produces some cash. At the recent price of $11.73, the shares look neither clearly cheap nor expensive against the company's weak earnings and small cash flow relative to its market value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-08-31) · fiscal Q3 2026 10-Q (period ended 2026-02-28) · fiscal Q2 2026 10-Q (period ended 2025-11-30) · fiscal Q1 2026 10-Q (period ended 2025-08-31) · FY2026 10-K (period ended 2026-05-31) · FY2025 10-K (period ended 2025-05-31) · FY2024 10-K (period ended 2024-05-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer